Key result
Dexmedetomidine was suggested to reduce mortality, major complications, and length of stay in cardiac surgery patients, though inconsistent results highlight the need for high-quality trials.
Why the study?
Dexmedetomidine is increasingly used in cardiac surgery patients, but studies and clinical trials have shown inconsistent results regarding its clinical effects.
Does dexmedetomidine reduce mortality, major complications, and length of stay in patients who underwent cardiac surgery?
Does dexmedetomidine reduce mortality, major complications, and length of stay in patients who underwent cardiac surgery?
Dexmedetomidine may improve clinical outcomes including mortality and length of stay in cardiac surgery patients, though high-quality randomized trials are needed to confirm these findings.
Answers are grounded in this paper and cite their sources.
Should not yet change practice in cardiac surgery; leaves open a mortality benefit pending randomized confirmation.
Dexmedetomidine, an alpha-2 adrenoreceptor agonist that is widely used as a sedative medication, is becoming more and more attractive in clinical application on cardiac surgery patients. In this review, we aim to summarize and discuss both retrospective studies and clinical trials regarding the effect of dexmedetomidine on patients who underwent cardiac surgery (including coronary artery bypass grafting, valve surgery, aortic surgery, percutaneous coronary intervention, and so on), which illustrates that the clinical effects of dexmedetomidine could effectively reduce mortality, major complications, and the intensive care unit and hospital length of stay without comprising safety. In addition, inconsistent results from both retrospective studies and clinical trials have also been demonstrated. Although the effectiveness and safety of dexmedetomidine on cardiac surgery patients is suggested, high-quality clinical trials are needed for further verification.
No takes yet. Share an insight, caveat, or question.
Xiao et al. (2023) conducted a review in Cardiac surgery. Dexmedetomidine was evaluated on Mortality, major complications, and intensive care unit and hospital length of stay. Dexmedetomidine was suggested to reduce mortality, major complications, and length of stay in cardiac surgery patients, though inconsistent results highlight the need for high-quality trials.
Synapse has enriched 10 related papers. Consider them for comparative context: